Core Viewpoint - The stock of Giant Bio (02367) has dropped over 4%, currently trading at 58.9 HKD with a transaction volume of 272 million HKD, following allegations regarding the quality of its collagen products [1] Group 1: Company Response and Allegations - Huaxi Bio has officially responded to the allegations surrounding Dr. Hao Yu, stating that it has conducted tests with multiple third-party institutions, revealing that the recombinant collagen content in related products did not meet standards [1] - Huaxi Bio has submitted dozens of test reports to the National Medical Products Administration, indicating a serious approach to addressing the quality concerns raised [1] - The controversy began in May when beauty blogger Dr. Hao Yu accused Giant Bio's product "Collagen Stick" of having a recombinant collagen content of only 0.0177%, significantly below the 0.1% non-trace addition standard [1] Group 2: Ongoing Disputes and Company Statements - Giant Bio quickly denied the allegations, asserting that its products comply with regulations and that internal testing results exceed the 0.1% standard [1] - On June 1, Huaxi Bio publicly supported Dr. Hao Yu, intensifying the conflict between the two parties [1] - Following a series of exchanges, Giant Bio acknowledged on June 23 that its existing quality standards, testing methods, and labeling have shown limitations in certain aspects [1]